GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » XWELL Inc (NAS:XWEL) » Definitions » Sloan Ratio %

XWELL (XWEL) Sloan Ratio % : -44.41% (As of Dec. 2023)


View and export this data going back to 2010. Start your Free Trial

What is XWELL Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

XWELL's Sloan Ratio for the quarter that ended in Dec. 2023 was -44.41%.

Warning Sign:

When sloan ratio (-44.41)% higher than 25% or lower than -25%, earnings are more likely to be made up of accruals.

As of Dec. 2023, XWELL has a Sloan Ratio of -44.41%, indicating earnings are more likely to be made up of accruals.


XWELL Sloan Ratio % Historical Data

The historical data trend for XWELL's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XWELL Sloan Ratio % Chart

XWELL Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Sloan Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -65.57 -59.27 -4.76 37.19 -44.41

XWELL Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 37.19 40.85 38.40 22.73 -44.41

Competitive Comparison of XWELL's Sloan Ratio %

For the Diagnostics & Research subindustry, XWELL's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XWELL's Sloan Ratio % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, XWELL's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where XWELL's Sloan Ratio % falls into.



XWELL Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

XWELL's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2023 )-Cash Flow from Operations (A: Dec. 2023 )
-Cash Flow from Investing (A: Dec. 2023 ))/Total Assets (A: Dec. 2023 )
=(-27.741--16.074
-5.65)/38.993
=-44.41%

XWELL's Sloan Ratio for the quarter that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Dec. 2023 )
=(-27.741--16.074
-5.65)/38.993
=-44.41%

XWELL's Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was -5.509 (Mar. 2023 ) + -5.73 (Jun. 2023 ) + -9.918 (Sep. 2023 ) + -6.584 (Dec. 2023 ) = $-27.74 Mil.
XWELL's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 was -5.865 (Mar. 2023 ) + -2.753 (Jun. 2023 ) + -4.255 (Sep. 2023 ) + -3.201 (Dec. 2023 ) = $-16.07 Mil.
XWELL's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 was -3.29 (Mar. 2023 ) + -0.48 (Jun. 2023 ) + 2.598 (Sep. 2023 ) + 6.822 (Dec. 2023 ) = $5.65 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


XWELL  (NAS:XWEL) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Dec. 2023, XWELL has a Sloan Ratio of -44.41%, indicating earnings are more likely to be made up of accruals.


XWELL Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of XWELL's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


XWELL (XWEL) Business Description

Traded in Other Exchanges
N/A
Address
254 West 31st Street, 11th Floor, New York, NY, USA, 10001
XWELL Inc is a health and wellness holding company. It is an airport retailer of spa services through XpresSpa locations, offering travelers premium spa services, including massage, nail, and skincare, as well as spa and travel products. It operates four reportable operating segments: XpresCheck, XpresSpa, Treat, and HyperPointe. XpresSpa is an airport retailer of wellness services and related products. Treat is a travel health and wellness brand that offers in-airport spa and wellness medical services. XpresCheck provides Covid-19 screening and diagnostic testing in partnership with the CDC. HyperPointe is a digital healthcare and data analytics relationship company.
Executives
Suzanne A. Scrabis officer: Chief Financial Officer C/O XWELL, INC., 254 WEST 31ST STREET, 11TH FLOOR, NEW YORK NY 10001
Robert Weinstein director 3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS NV 89169
Scott R Milford officer: Chief Executive Officer C/O TOWN SPORTS INTERNATIONAL, LLC, 5 PENN PLAZA, NEW YORK NY 10001
Bruce Bernstein director 780 THIRD AVENUE, 12TH FLOOR, NEW YORK NY 10017
Ezra Ernst officer: See Remarks C/O XPRESSPA GROUP, INC., 254 WEST 31ST STREET, 11TH FLOOR, NEW YORK NY 10001
Omar Haynes officer: VP Treas & Fi & Interim CFO C/O XPRESSPA GROUP, INC., 254 WEST 31ST STREET, 11TH FLOOR, NEW YORK NY 10001
Doug Satzman director, officer: Chief Executive Officer 780 THIRD AVENUE, 12TH FLOOR, NEW YORK NY 10017
James A. Berry officer: Chief Financial Officer C/O XPRESSPA GROUP, INC., 254 WEST 31ST STREET, 11TH FLOOR, NEW YORK NY 10001
Michael Lebowitz director 780 THIRD AVENUE, 12TH FLOOR, C/O XPRESSPA GROUP, INC., NEW YORK NY 10017
Donald E. Stout director 780 THIRD AVENUE, 15TH FLOOR, NEW YORK NY 10017
Mistral Spa Holdings, Llc 10 percent owner C/O MISTRAL CAPITAL MANAGEMENT, LLC, 650 FIFTH AVENUE, 31ST FLOOR, NEW YORK NY 10019
Mistral Capital Management, Llc 10 percent owner 650 FIFTH AVENUE, 31ST FLOOR, NEW YORK NY 10019
Andrew R Heyer other: Former director and 10% owner 501 MADISON AVENUE, FLOOR 5, NEW YORK NY 10019
Calm.com, Inc. 10 percent owner 140 2ND STREET, THIRD FLOOR, SAN FRANCISCO CA 94105
Edward Jankowski officer: SVP; CEO of XpresSpa C/O FORM HOLDINGS CORP., 780 THIRD AVENUE, 12TH FLOOR, NEW YORK NY 10017